Peripheral biomarkers for dementia are few and far between. Despite research into blood plasma/serum biomarkers for dementia diagnostics, there is a lack of information on erythrocytes and their vast proteomes as potential biomarkers. This review identifies a number of relevant and potentially promising erythrocyte biomarkers for various subtypes of dementia. These include erythrocyte morphology, oxidative stress, and erythrocyte membrane proteins such as the glucose transporter (GLUT-1), amyloid-β, IgG, Hsp90, calpain-1, and band 3 protein. Of those proteins identified Hsp90, amyloid-β, calpain-1 and band 3 show the most promise as pre-clinical biomarkers. However, the most intriguing aspect of erythrocytes is their changed morphology in dementia. The altered morphology not only could be used as a diagnostic biomarker but may be crucial in early pathogenesis of the disease. Further work must be done to establish the pathological connection between the periphery and central disease processes.
IulitaMF, OwerA, BaroneC, PentzR, GubertP, RomanoC, CantarellaRA, EliaF, BuonoS, RecuperoM, RomanoC, CastellanoS, BoscoP, Di NuovoS, DragoF, CaraciF, CuelloAC (2016) An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimers Dement12, 1132–1148.
2.
HanssonO, ZetterbergH, VanmechelenE, VandersticheleH, AndreassonU, LondosE, WallinA, MinthonL, BlennowK (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging31, 357–367.
3.
KiddleSJ, SattleckerM, ProitsiP, SimmonsA, WestmanE, BazenetC, NelsonSK, WilliamsS, HodgesA, JohnstonC, SoininenH, KłoszewskaI, MecocciP, TsolakiM, VellasB, NewhouseS, LovestoneS, DobsonRJ (2014) Candidate blood proteome markers of Alzheimer’s disease onset and progression: A systematic review and replication study. J Alzheimers Dis38, 515–531.
4.
Mukaetova-LadinskaEB, Abdel-AllZ, DoddsS, AndradeJ, Alves da SilvaJ, KalariaRN, O’BrienJT (2012) Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer’s disease: Findings from a pilot study. Age Ageing41, 408–412.
5.
ZellnerM, BaurederM, RappoldE, BugertP, KotzailiasN, BabelukR, BaumgartnerR, AttemsJ, GernerC, JellingerK, RothE, OehlerR, UmlaufE (2012) Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer’s disease but not in non-demented Parkinson’s disease patients. J Proteomics75, 2080–2092.
6.
VeitingerM, VargaB, GuterresSB, ZellnerM (2014) Platelets, a reliable source for peripheral Alzheimer’sdisease biomarkers?Acta Neuropathol Commun16, 65.
7.
ManzinePR, BarhamEJ, ValeFA, Selistre-de-AraújoHS, PavariniSC, CominettiMR (2014) Platelet a disintegrin and metallopeptidase 10 expression correlates with clock drawing test scores in Alzheimer’s disease. Int J Geriatr Psychiatry29, 414–420.
8.
Mukaetova-LadinskaEB, Abdel-AllZ, AndradeJ, Alves da SilvaJ, O’BrienJT, KalariaRN (2015) Plasma and platelet clusterin ratio is altered in Alzheimer’s disease patients with distinct neuropsychiatric symptoms: Findings from a pilot study. Int J Geriatr Psychiatry30, 368–375.
9.
Rezai-ZadehK, GateD, SzekelyCA, TownT (2009) Can peripheral leukocytes be used as Alzheimer’s disease biomarkers?Expert Rev Neurother9, 1623–1633.
10.
EsterasN, AlquézarC, de la EncarnaciónA, VillarejoA, Bermejo-ParejaF, Martín-RequeroA (2013) Calmodulin levels in blood cells as a potential biomarker of Alzheimer’s disease. Alzheimers Res Ther5, 55.
11.
LuthES, BartelsT, DettmerU, KimNC, SelkoeDJ (2015) Purification of α-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry54, 279–292.
12.
BosmanGJ, WerreJM, WillekensFL, NovotnýVM (2008) Erythrocyte ageing in vivo and in vitro: Structural aspects and implications for transfusion. Transfus Med18, 335–347.
13.
KubotaK, ShirakuraT, OruiT, MurataniM, MakiT, TamuraJ, MoritaT (1991) Changes in the blood cell counts with aging. Nihon Ronen Igakkai Zasshi28, 509–514.
14.
BosmanGJ, BartholomeusIG, de ManAJ, van KalmthoutPJ, de GripWJ (1991) Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer’s disease’. Neurobiol Aging12, 13–18.
15.
KikoT, NakagawaK, SatohA, TsudukiT, FurukawaK, AraiH, MiyazawaT (2012) Amyloid beta levels in human red blood cells. PLoS One7, p.e49620.
16.
DodgeJT, MitchellC, HanahanDJ (1963) The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys100, 119–130.
17.
HarrisF, SmithSK, BellJ (2001) Physical properties of eryhtrocyte ghosts that determine susceptibility to secretory phospholipase A2. J Biol Chem276, 22722–22731.
18.
MohantyJG, ShuklaHD, WilliamsonJD, LaunerLJ, SaxenaS, RifkindJM (2010) Alterations in the red blood cell membrane proteome in Alzheimer’s subjects reflect disease-related changes and provide insight into altered cell morphology. Proteome Sci8, 11.
19.
GoodmanSR, KurdiaA, AmmannL, KakhniashviliD, DaescuO (2007) The human red blood cell proteome and interactome. Exp Biol Med (Maywood)232, 1391–1408.
20.
PasiniEM, KirkegaardM, MortensenP, LutzHU, ThomasAW, MannM (2006) In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood108, 791–801.
21.
MohantyJG, EckleyDM, WilliamsonJD, LaunerLJ, RifkindJM (2008) Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer’s disease?Adv Exp Med Biol614, 29–35.
22.
BesterJ, BuysAV, LipinskiB, KellDB, PretoriusE (2013) High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer’s disease. Front Aging Neurosci5, 88.
23.
LanJ, LiuJ, ZhaoZ, XueR, ZhangN, ZhangP, ZhaoP, ZhengF, SunX (2015) The peripheral blood of Abeta binding ERCs as a biomarker for diagnosis of Alzheimer’s disease. Age Ageing44, 458–464.
24.
MerkelDL, ChengCH, CastellinoFJ, ChibberBA (1996) Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer’s disease. Blood Coagul Fibrinolysis7, 650–658.
25.
LucasHR, RifkindJM (2013) Considering the vascular hypothesis of Alzheimer’s disease: Effect of copper associated amyloid on red blood cells. Adv Exp Med Biol765, 131–138.
26.
JayakumaR, KusiakJW, ChrestFJ, DemehinAA, MuraliJ, WerstoRP, NagababuE, RaviL, RifkindJM (2003) Red cell perturbations by amyloid beta-protein. Biochem Biophys Acta1622, 20–28.
JäremoP, MilovanovicM, NilssonS, BullerC, PostC, WinbladB (2011) Alzheimer’s disease is characterized by more low-density erythrocytes with increased volume and enhanced β-amyloid x-40 content. J Intern Med270, 489–492.
29.
ButterfieldDA, PalmieriDA (1990) Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer’s disease, with erythrocyte membranes. Free Radic Res Commun9, 361–366.
MohandasN, GallagherPG (2008) Red cell membrane: Past, present, and future. Blood112, 3939–3948.
32.
AndresdottirMB, SigfussonN, SigvaldasonH, GudnasonV (2003) Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol158, 844–851.
33.
McMahonCJ, HopkinsS, VailA, KingAT, SmithD, IllingworthKJ, ClarkS, RothwellNJ, TyrrellPJ (2013) Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage. J Neurointerv Surg5, 512–517.
34.
GoodallHB, ReidAH, FindlayDJ, HindC, KayJ, CoghillG (1994) Irregular distortion of the erythrocytes (acanthocytes, spur cells) in senile dementia. Dis Markers12, 23–41.
35.
ChenH, KhanAA, LiuF, GilliganDM, PetersLL, MessickJ, Haschek-HockWM, LiX, OstafinAE, ChishtiAH (2007) Combined deletion of mouse dematin-headpiece and beta-adducin exerts a novel effect on the spectrin-actin junctions leading to erythrocyte fragility and hemolytic anemia. J Biol Chem282, 4124–4135.
36.
MosconiL (2013) Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging1. doi: 10.1007/s40336-013-0026-y
37.
GiavarottiL, SimonKA, AzzalisLA, FonsecaFL, LimaAF, FreitasMC, BrunialtiMK, SalomãoR, MoscardiAA, MontañoMB, RamosLR, JunqueiraVB (2013) Mild systemic oxidative stress in the subclinical stage of Alzheimer’s disease. Oxid Med Cell Longev2013, 609019.
38.
KawamotoEM, MunhozCD, GlezerI, BahiaVS, CaramelliP, NitriniR, GorjãoR, CuriR, ScavoneC, MarcourakisT (2005) Oxidative state in platelets and erythrocytes in aging and Alzheimer’s disease. Neurobiol Aging26, 857–864.
39.
ArbosKA, ClaroLM, BorgesL, SantosCA, Weffort-SantosAM (2008) Human erythrocytes as a system for evaluating the antioxidant capacity of vegetable extracts. Nutr Res28, 457–463.
40.
SivilottiML (2004) Oxidant stress and haemolysis of the human erythrocyte. Toxicol Rev23, 169–188.
41.
BryszewskaM, ZavodnikIB, NiekurzakA, SzoslandK (1995) Oxidative processes in red blood cells from normal and diabetic individuals. Biochem Mol Biol Int37, 345–354.
42.
PandeyKB, RizviSI (2011) Biomarkers of oxidative stress in red blood cells. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub155, 131–136.
43.
VáradyG, SzabóE, FehérA, Boglárka ZámbóAN, PákáskiM, JankaZ, SarkadiB (2015) Alterations of membrane protein expression in red blood cells of Alzheimer’s disease patients. Alzheimers Dement (Amst)1, 334–338.
44.
HarikSI, BehmandRA, ArafahBM (1991) Chronic hyperglycemia increases the density of glucose transporters in human erythrocyte membranes. J Clin Endocrinol Metab72, 814–818.
45.
AmurS, LaVangeL, ZinehI, Buckman-GarnerS, WoodcockJ (2015) Biomarker qualification: Toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther98, 34–46.
NakagawaK, KikoT, MiyazawaT, SookwongP, TsudukiT, SatohA, MiyazawaT (2011) Amyloid β-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett585, 1249–1254.
48.
MattsonMP, BegleyJG, MarkRJ, FurukawaKA (1997) β25-35 induces rapid lysis of red blood cells: Contrast with aβ1-42 and examination of underlying mechanisms. Brain Res771, 147–153.
49.
ShringarpureR, GruneT, SitteN, DaviesKJ (2000) 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: Possible importance in Alzheimer’sdisease. Cell Mol Life Sci57, 1802–1809.
50.
GregoriL, FuchsC, Figueiredo-PereiraME, Van NostrandWE, GoldgaberD (1995) Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem270, 19702–19708.
51.
KayMM (2004) Band 3 and its alterations in health and disease. Cell Mol Biol (Noisy-le-grand)50, 117–138.
FerraliM, SignoriniC, CiccoliL, BambagioniS, RossiV, PompellaA, ComportiM (2000) Protection of erythrocytes against oxidative damage and autologous immunoglobulin G (IgG) binding by iron chelator fluor-benzoil-pyridoxal hydrazine. Biochem Pharmacol59, 1365–1373.
60.
SalhanyJM, CordesKS, SloanRL (2001) Characterization of immunoglobulin binding to isolated human erythrocyte membranes: Evidence for selective, temperature-induced binding of naturally occurring autoantibodies to the cytoskeleton. Biochim Biophys Acta1511, 168–180.
61.
KayMM (1975) Mechanism of removal of senescent cells by human macrophages in situ. Proc Natl Acad Sci U S A72, 3521–3525.
BosmanGJ, VisserFE, De ManAJ, De GripWJ (1993) Erythrocyte membrane changes of individuals with Down’s syndrome in various stages of Alzheimer-type dementia. Neurobiol Aging14, 223–228.
64.
BosmanGJ, Van der LindenPA, BartholomeusIG, De ManAJ, De GripWJ, Van KalmthoutPJ (1998) Erythrocyte aging in the demented elderly: A fluctuating process?Mech Ageing Dev100, 53–58.
65.
WilsonJS, MruthintiS, BuccafuscoJJ, SchadeRF, MitchellMB, HarrellDU, GulatiNK, MillerLS (2009) Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance. J Gerontol A Biol Sci Med Sci64, 264–271.
66.
NixonRA, SaitoKI, GrynspanF, GriffinWR, KatayamaS, HondaT, MohanPS, SheaTB, BeermannM (1994) Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer’s disease. Ann N Y Acad Sci747, 77–91.
67.
WieschhausA, KhanA, ZaidiA, RogalinH, HanadaT, LiuF, De FranceschiL, BrugnaraC, RiveraA, ChishtiAH (2012) Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochem J448, 141–152.
68.
KarlssonJO, BlennowK, HolmbergtB, JansonI, KarlssonI, NilssonE, WallinA, GottfriesCG (1992) Increased proteolytic activity in erythrocytes from patients with alzheimer’s disease. Dement Geriatr Cogn Dis3, 200–204.
69.
De FranceschiL, FrancoRS, BertoldiM, BrugnaraC, MattéA, SicilianoA, WieschhausAJ, ChishtiAH, JoinerCH (2013) Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB J27, 750–759.
70.
TrincheseF, Fa’M, LiuS, ZhangH, HidalgoA, SchmidtSD, YamaguchiH, YoshiiN, MathewsPM, NixonRA, ArancioO (2008) Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest118, 2796–2807.
71.
MorelliA, GrassoM, MeloniT, ForteleoniG, ZocchiE, De FloraA (1987) Favism: Impairment of proteolytic systems in red blood cells. Blood69, 1753–1758.
72.
WhitesellL, LindquistSL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer5, 761–772.
73.
SalminenA, OjalaJ, KaarnirantaK, HiltunenM, SoininenH (2011) Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease. Prog Neurobiol93, 99–110.
74.
KhalidS, PaulS (2014) Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer’s disease. Med Hypotheses83, 39–46.
75.
AnthonySG, SchipperHM, TavaresR, HovanesianV, CortezSC, StopaEG, JohansonCE (2003) Stress protein expression in the Alzheimer-diseased choroid plexus. J Alzheimers Dis5, 171–177.
CristalliDO, ArnalN, MarraFA, de AlanizM, MarraCA (2012) Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci314, 48–56.
81.
ChangTL, ChangCJ, LeeWY, LinMN, HuangYW, FanK (2009) The roles of ubiquitin and 26S proteasome in human obesity. Metabolism58, 1643–1648.
82.
GilL, SiemsW, MazurekB, GrossJ, SchroederP, VossP, GruneT (2006) Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res40, 495–505.
